Stockreport

H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio's (CLYM) Budoprutug Across Clinical Tracks [Yahoo! Finance]

Climb Bio, Inc.  (CLYM) 
PDF Wainwright analyst Raghuram Selvaraju raised the firm's price target on Climb Bio to $11 from $9, while maintaining a Buy rating on the shares. This sentiment was announ [Read more]